Janez, Andrej http://orcid.org/0000-0002-6594-5254
Muzurovic, Emir
Bogdanski, Pawel
Czupryniak, Leszek
Fabryova, Lubomira
Fras, Zlatko
Guja, Cristian
Haluzik, Martin
Kempler, Peter
Lalic, Nebojsa
Mullerova, Dana
Stoian, Anca Pantea
Papanas, Nikolaos
Rahelic, Dario
Silva-Nunes, José
Tankova, Tsvetalina
Yumuk, Volkan
Rizzo, Manfredi
Funding for this research was provided by:
Novo Nordisk
Article History
Received: 29 April 2024
Accepted: 20 June 2024
First Online: 11 July 2024
Declarations
:
: The authors have given lectures, received honoraria and research support, and participated in conferences, advisory boards, and clinical trials sponsored by many pharmaceutical companies. Yet, no pharmaceutical company had any role in the scientific content of the present article, which has been written independently, and reflects only the opinion of the authors, without any role of the industry. The following conflict of interests were reported: Andrej Janez has served as a consultant and is on Speakers Bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Medtronic, Abbott, Novo Nordisk, Novartis and Swixx. Emir Muzurovic has given lectures, participated in conferences and advisory boards sponsored by several pharmaceutical companies, including Novo Nordisk, Sanofi, AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, Medtronic and Servier. Pawel Bogdanski has participated in a Data Safety Monitoring Board or Advisory Board of Novo Nordisk, Boehringer Ingelheim, Eli Lilly, Valeant and received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Novo Nordisk, Boehringer Ingelheim, Eli Lilly, Valeant and Sanofi Aventis. Ľubomíra Fábryová has received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Eli Lilly, Novo Nordisk (Slovakia), Boehringer Ingelheim, Sandoz, Servier and Krka. Cristian Guja has participated in scientific advisory boards and received lecturing fees from AstraZeneca, Berlin Chemie Mennarini, Boehringer Ingelheim, Eli Lilly, Krka, Novo Nordisk, Pfizer, Sandoz, Sanofi, Servier and Viatris. Martin Haluzík has received consulting fees and payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Inghelheim, Eli Lilly, Merck, Novo Nordisk, Novartis, Pfizer, Sandoz, Sanofi, Krka. Martin Haluzik is an Advisory Board Member of<i> Diabetes Therapy</i>. He was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Péter Kempler has received consulting fees and payment or honoraria for lectures, presentations from Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Boehringer Ingelheim, Richter-Gedeon. Nebojsa M. Lalic has received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Novo Nordisk, Medtronic, Boehringer Ingelheim. Dana Mullerova has received consulting fees from Eli Lilly, and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Novo Nordisk. Anca Pantea Stoian has received consulting fees and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, Amgen, Boheringer Inghelheim, Coca Cola, Eli Lilly, Medochemie, Merck, MSD, Medtronic, Novo Nordisk, Novartis, Pfizer, Sandoz Sanofi Servier. Nikolaos Papanas has received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Sanofi Aventis, Eli Lilly, Vianex, Viatris, Menarini, Roche, Abbott, Medtronic, ELPEN and Galenica. Nikolaos Papanas is an Editorial Board member of<i> Diabetes Therapy</i>. He was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Dario Rahelić has received consulting fees and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Abbott, Amgen, AstraZeneca, Bayer, Bauerfeind, Boehringer lngelheim, Dexcom, Eli Lilly, Johnson&Johnson, Krka, Medtronic, Merck, MSD, Novartis, Novo Nordisk, Pliva, Roche, Sandoz, Sanofi, Salvus, Takeda, Viatris. José Silva-Nunes has received consulting fees and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, Bial, Boehringer lngelheim, Eli Lilly, Medinfar, Novo Nordisk, Sanofi. Tsvetalina Tankova has received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi, Servier, Merck, MSD, Worwag. Volkan Yumuk has received funding from Eli Lilly for providing single advisor activity and Novo Nordisk for providing educational sessions and attending advisory boards. Manfredi Rizzo has given lectures, received honoraria and research support and participated in conferences, advisory boards and clinical trials sponsored by many pharmaceutical companies, including Amgen, AstraZeneca, Biodexa, Boehringer Ingelheim, Kowa, Eli Lilly, Meda, Mylan, Merck Sharp & Dohme, Novo Nordisk, Novartis, Roche, Sanofi and Servier. Manfredi Rizzo is an Editorial Board member of<i> Diabetes Therapy</i>. He was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Leszek Czupryniak and Zlatko Fras have nothing to disclose.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors therefore, ethical approval was not necessary.